Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David Loew | MD, CEO & Director | 2.22M | -- | 1967 |
| Mr. Aymeric Le Chatelier | Exec. VP & Group CFO | -- | -- | 1969 |
| Dr. Aidan Murphy Ph.D. | Exec. VP of Technical Operations | -- | -- | 1966 |
| Mr. Craig Marks | Vice-Pres of Investor Relations | -- | -- | -- |
| Mr. Francois Garnier | Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer | -- | -- | 1962 |
| Ms. Gwenan White | Exec. VP of Communications, Public Affairs & Sustainability | -- | -- | -- |
| Mr. Regis Mulot | Exec. VP & Chief HR Officer | -- | -- | 1966 |
| Ms. Dominique Bery | Head of Nordics & Baltics | -- | -- | 1971 |
| Dr. Yan Moore M.D. | Sr. VP & Head of Oncology Therapeutic Area | -- | -- | 1967 |
| Dr. Alexander McEwan | Vice-Pres & Head of Radiopharmaceuticals | -- | -- | -- |
Ipsen S.A.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 5,300
Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Corporate Governance
Upcoming Events
February 13, 2025 at 6:00 AM UTC
Ipsen S.A. Earnings Date
Recent Events
June 2, 2023 at 12:00 AM UTC
Ex-Dividend Date